OGT 2378

Drug Profile

OGT 2378

Latest Information Update: 22 Jun 2007

Price : $50

At a glance

  • Originator UCB
  • Class Antineoplastics; Imino sugars; Piperidines
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Malignant melanoma

Most Recent Events

  • 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
  • 15 Sep 2003 A preclinical study has been added to the adverse events, pharmacokinetics and Cancer pharmacodynamics sections
  • 12 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top